Kornimate/medical-research-clean huggingface dataset:
recurrent glomerulonephritis after renal transplantation

Conditions: Glomerulonephritis

Summary: glomerulonephritis (gn) is the leading cause of end-stage renal disease in 30% to 50% of patients who receive a renal transplant. the exact prevalence of either recurrent or de novo gn is unknown since a considerable number of patients never undergo allograft biopsy, leaving gn underdiagnosed. the aim of this study is to evaluate the effects of recurrent gn on the prevalence, risk factors, clinicopathological features, and outcome of renal transplant recipients.

glomerulonephritis is the leading cause of end-stage renal disease in 30% to 50% of patients who receive a renal transplant. even though recurrent or de novo posttransplant primary gn is the third most frequent cause of renal allograft loss after renal transplantation, different recurrence rates have been reported in different patient series worldwide. with the implementation of diverse and improved immunosuppressive treatment regimens and prolongation of graft survival, renal allograft loss caused by recurrent or de novo gn will be more important than ever. data obtained from comparing patients who have recurrent primary gn against patients with non-recurrent gn and renal transplant recipients with non-gn etiology shall bring new approaches to the daily practice of managing patients with gn and renal failure, assessing them as transplant candidates and applying new therapies.

Eligibility criteria:
inclusion criteria: * patients who underwent a renal transplantation because of an end-stage renal disease caused by primary glomerulonephritis and have biopsy-proven recurrent primary glomerulonephritis (recurrent gn group) * patients who underwent a renal transplantation because of an end-stage renal disease caused by primary glomerulonephritis and have no signs of recurrence (non-recurrent gn group) * patients who underwent a renal transplantation because of an end-stage renal disease linked to an etiology other than primary glomerulonephritis (non-gn group) exclusion criteria: * patients who are unwilling or unable to consent
a study to evaluate pharmacodynamics, safety, tolerability and pharmacokinetics of mt-3995 in type ii diabetic nephropathy subjects with albuminuria and moderately decreased gfr

Conditions: Diabetic Nephropathy

Summary: the purpose of this study is to evaluate pharmacodynamics, safety, tolerability and pharmacokinetics of mt-3995 in type ii diabetic nephropathy subjects with albuminuria and moderately decreased gfr


Eligibility criteria:
inclusion criteria: * subjects with type ii diabetic nephropathy, who have been treated with angiotensin converting enzyme-inhibitor (ace-i) or angiotensin ii receptor blocker (arb) * glycosylated haemoglobin (hba1c) ≤10.5% * an estimated glomerular filtration rate (egfr) ≥30-\<60 ml/min/1.73m\^2 * subject with albuminuria exclusion criteria: * history of type i diabetes, pancreas or β-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy * serum potassium level \ 5.0 mmol/l * subjects who had acute kidney injury (aki) within 3 months prior to baseline or have undergone renal dialysis at any time prior to randomisation * subjects with a history of renal transplant * subjects with clinically significant hypotension

Keywords: diabetic nephropathy
modifiable variables in parkinsonism (mvp)

Conditions: Parkinson's Disease; Parkinsonism; MSA - Multiple System Atrophy; Progressive Supranuclear Palsy; Shy-Drager Syndrome; Corticobasal Degeneration; Dementia With Lewy Bodies; Pick Disease; Olivopontocerebellar Atrophies

Summary: we are trying to identify factors associated with improved quality of life and fewer pd symptoms. we are attempting to identify practices, beliefs, and therapies used by individuals who report excellent quality of life, few pd symptoms, and reduced rates of progression. after agreeing to participate, we will ask participants to fill our questionnaires about their experience with pd, their health in general, along with their food intake every six months for five years.

this is a prospective, observational study designed to describe disease progression, symptom change, quality of life, diet and lifestyle habits among patients with parkinson's disease (pd). this study will identify and describe those individuals with the highest quality of life and least amount of disease activity, in order to describe medication, diet, and lifestyle patterns associated with a lack of pd disease progression and high quality of life. participants will be asked to complete online surveys every six months for five years. the time requirement is about an hour to an hour and a half every six months. participants do not need to answer questions if they do not feel comfortable answering. at each six month time point we will send participants an email with the link to the cam care in pd survey, a questionnaire about health and wellbeing (completed in redcap). after participants have completed this survey we will send participants a link to the second survey, about dietary intake (completed on asa24.gov). because there is a designated window of time during which surveys must be completed, participants may receive a gentle reminder from us if time is running out. this study is not designed to provide care. participants are encouraged to consult with any providers you wish. participants will not directly benefit from the study, but information gathered during the course of this study may help us begin to assess the longer-term effects of complementary and integrative care on health, disease progression and quality of life in pd patients.

Eligibility criteria:
inclusion criteria: * parkinson's disease (pd) * parkinsonism * parkinson-plus syndromes (e.g. multiple system atrophy (msa), progressive supranuclear palsy (psp), corticobasal degeneration (cbgd), dementia with lewy bodies) * must have online access, an email address, basic computer literacy * must be willing to complete online surveys every 6 months for 5 years exclusion criteria: * inability to read/write english * inability or unwillingness to complete surveys every six (6) months (\~90 min)

Keywords: parkinson's disease pd complementary and alternative cam
arthroscopic guided synovial biopsies

Conditions: Temporomandibular Arthritis

Summary: to detect accuracy of serology in diagnosis of temporomandibular joint arthritis.

according to a search of previously published studies on accuracy of serology no sensitivity or specificity data was found regarding accurate detection of arthritis through serology, hence the aim of this study is to detect accuracy of serology in diagnosis of temporomandibular joint arthritis.

Eligibility criteria:
inclusion criteria: * patients suffering from temporomandibular joint arthritis. * patients should be free from any systemic disease that may affect normal healing and predictable outcome. * patients who will agree to the consent exclusion criteria: * patients with any systemic disease that may affect normal healing. * pregnant females. * patients with acute infection. * patients with bony ankyloses. * patients with risk of tumor dissemination.
indoleamine 2,3-dioxygenase (ido) activity in patients with chronic lymphocytic leukemia (cll)

Conditions: CLL

Summary: the activity of indoleamine 2,3-dioxygenase in patients with chronic lymphocytic leukemia (cll) is studied.

the activity of indoleamine 2,3-dioxygenase in patients with chronic lymphocytic leukemia (cll)is studied in patients and healthly controls.

Eligibility criteria:
inclusion criteria: * patients with cll and lymphocyte count \> 10 x 109/l exclusion criteria: * acute infection

Keywords: cll ido
hypofractionated stereotactic boost in prostate cancer

Conditions: Cancer

Summary: hypofractionated stereotactic boost radiation (prostate) after normofractionated radiotherapy (prostate + seminal vesicles).

the aim of this study is to assess the safety of hypofractionated stereotactic boost radiation (prostate) after normofractionated radiotherapy (prostate + seminal vesicles).

Eligibility criteria:
inclusion criteria: * prostate adenocarcinoma proved by histology * with at least one of this intermediate-risk criterias: * t2b * and/or psa between 10 et 20 ng/ml * and/or gleason score = 7 * prostatic volume ≤ 80 cc * no adenopathy(lymph node \< 1.5 cm on scanner or mri and/or in lymph node dissection) * no metastasis (bone scan) * age \>= 18 ans * no prior pelvic irradiation * no prior anticancer treatment (prostatectomy, chemotherapy, hormonotherapy \> 3 months) * performance status (ecog) \< 1 * no contraindication of fiducials implantation, hemostasis disorders must be treated before the implantation * life expectancy \>= 10 weeks * patient affiliated to health insurance * informed consent signed by the patient exclusion criteria: * cancer no histologically proved * unfavorable-risk(t2c and/or psa \> 20 ng/ml and/or gleason \> 7) * favorable-risk(t1c t2a and psa \< 10 ng/ml and gleason \< 7) * t3 and t4 * history of cancer uncontrolled and/or treated since less of 5 years (except basal cell carcinoma of the skin) * contraindication to mri * ipss score \> 10 * recurrent or metastatic disease * allergy to gold * patient already included in another therapeutic trial with an experimental molecule * unable for medical follow-up (geographic, social or mental reasons)

Keywords: prostate cancer
hierarchy of vision

Conditions: Neurologic Signs

Summary: little is known about the exact role of feedback in cortical processing. hypotheses on its function range from attentional control to the transmission of bayesian priors in the interpretation of sensory events, such as in the theory of predictive coding. recent advances in identification of functional signatures of feedback and feedforward signal, as well as additional techniques based on causal relations in signal processing open a unique methodology for probing such processes in awake and behaving organisms and testing these theories and more generally the hierarchical processing between cortical areas. the objective of this project is to study feedback and feedforward relations and localization in the well established pathways between cortical areas v1 and medial temporal (mt) that have been implicated in early integration processes in motion perception.


Eligibility criteria:
inclusion criteria: * aged between 18 and 40 years old * affiliated to a social security scheme * be right-handed * have signed the informed consent exclusion criteria: * subjects with a neurological or psychiatric history * subjects with visual disturbances not corrected * pregnant, lactating or childbearing women without contraception. * persons under guardianship, trusteeship or any other administrative or judicial measure of deprivation of rights or liberty, as well as adults protected by law. * participants refusing to be informed of the results of the medical examination. * participants refusing to be informed of the possible detection of an anomaly. * volunteers with contraindications to the mri examination: people using a pacemaker or an insulin pump, persons wearing a metal prosthesis or an intracerebral clip as well as claustrophobic subjects, neurosensory stimulator or implantable defibrillator, cochlear implants, ferromagnetic foreign body ocular or cerebral close to the nerve structures, agitation of the subject (non-cooperating or agitated subjects), ventriculoperitoneal neurosurgical bypass valves, dental apparatus.

Keywords: vision perception bold activity
selenoprotein and renalase blood levels in patients with hypertensive heart disease and obstructive sleep apnea

Conditions: Hypertension; Obstructive Sleep Apnea

Summary: the aim of the study is to determine whether selenoprotein activity and blood renalase level correlate with subclinical hypertensive heart disease and obstructive sleep apnea. the correlation will be assessed using selected electrocardiographic, ultrasound and laboratory indicators.

the study will be conducted in the department and clinic of internal medicine, occupational diseases, hypertension and clinical oncology at borowska 213 street in wroclaw. this decision follows the high percentage of people with obstructive sleep apnea and hypertension among those hospitalized in the clinic and also the wide availability of research tools in the hospital. 150 more patients with hypertension and obstructive sleep apnea will be included in the planned observational study. the study is observational, research procedures are non-invasive and no additional medical experiment is planned. the study was approved by the bioethics committee of the wroclaw medical university. patients enrolled in the study will be asked to share the results of their previously performed examinations or, in case they do not have any, new examinations will be performed to complement the diagnostic process of hypertension and obstructive sleep apnea. the planned procedures include: medical interview, physical examination with basic anthropometric measurements (age, height, body weight); biochemical tests including blood selenium, selenoproteins, renalase and creatinine levels; total antioxidant status (tas), 24-hour holter electrocardiography, polysomnography, ultrasound assessment of peripheral vascular endothelial function and echocardiography. laboratory tests will be performed using commercially available standardized tests. the levels of selenoproteins, renalase and creatinine in the blood, as well as tas will be determined by elisa (enzyme-linked immunosorbent assay) in accordance with the instructions. blood selenium level will be measured by means of atomic absorption spectrometry (aas). 24-hour holter ecg monitoring will be performed using a lifecard cf recorder, followed by an analysis of the record by the impresario solo system (delmar reynolds, hertford, uk). ultrasound examination will be performed using the prosound alpha 6 (aloka inc, tokyo, japan).

Eligibility criteria:
inclusion criteria: * arterial hypertension exclusion criteria: * age \<18 * pregnancy * refusal to participate in the study

Keywords: hypertension renalase selenoprotein
a comparison of management strategies of asthma in pregnancy

Conditions: Asthma; Pregnancy

Summary: investigate differences in practice patterns in providers who may care for pregnant women with asthma exacerbations. the investigators believe that practitioners of different specialties will practice differently.

the goal of this investigation is to determine how physicians manage pregnant patients with asthma exacerbations using patient vignettes. vignettes or case studies have been shown in various areas of medicine to be an effective tool for surveying provider's knowledge and application of evidence-based guidelines (9,10,11,12). specifically, we plan on surveying physicians-in-training and attending physicians in emergency medicine, family medicine, internal medicine, obstetrics/gynecology, and pulmonary/critical care medicine at the ohio state university werner medical center via electronic mail. electronic mail addresses will be obtained from each department or division's training program director. we have presented multiple, fictional, case-based scenarios and short, multiple-choice questions where the responder indicates how they would manage the case. no existing patient data will be used in the scenarios. in addition, demographic data of the physician including length of time in practice, numbers of patients seen with asthma exacerbations per month, and comfort level with the national asthma education and prevention program guidelines (1). the survey is attached. physicians who do not respond to the first electronic mail will be sent one follow-up electronic mail with a second request to complete the survey. results from the questionnaires completed by each department/devision of physicians will be compared and analyzed for significant differences. the results will then be used to look for educational opportunities to improve the care of pregnant patients with asthma exacerbations.

Eligibility criteria:
inclusion criteria: * physicians-in-training and attending physicans at the ohio state university medical center emergency medicine, family medicine, internal medicine, obstetrics/gynecology, and pulmonary/critical care medicine at the ohio state university werner medical center
procedural advantages of a novel drug-eluting coronary stent

Conditions: Coronary Artery Disease

Summary: this study sought to compare procedural performance of a new coronary stent generation, that is already available in germany, with hitherto established current drug-eluting stents.


Eligibility criteria:
inclusion criteria: * cad for pci, consecutive patients exclusion criteria: * age under 18 * bare metal stents or scaffolds
biological markers for the diagnosis of central nervous system infective diseases

Conditions: Infection

Summary: bacterial meningitis is a potentially life-threatening disease that is associated with substantial neurological morbidity and mortality. accurate diagnosis is essential to improve outcome and prevent antibiotic overuse. here we try to explore new biological markers for the diagnosis of the central nervous system infection disease.

to investigate the diagnosis value of procalcitonin,interleukin-6, agiotensininⅱin the cerebrospinal fluid in the central nervous system infection disease.

Eligibility criteria:
inclusion criteria: 1. aged 13 years or older; 2. at least two of the following clinical characteristics:headache, fever, neck stiffness, mental symptoms or consciousness impairment or seizures 3. patients' family signed informed consent. exclusion criteria: 1. contraindications to lumbar puncture 2. patients with active malignancy

Keywords: procalcitonin interleukin-6 agiotensininⅱ
whole-body vibration versus kineso tape on nerve conduction in patient with diabetic peripheral neuropathy

Conditions: Diabetic Peripheral Neuropathy

Summary: the purpose of the study was to compare between effect of whole-body vibration and kineso tape on nerve conduction in patients with diabetic peripheral neuropathy.

diabetes is a huge and rapidly growing health problem worldwide. in 2019, international diabetes federation ( idf) estimated that the number of people with diabetes was 463 million and expected to be 578 million by 2030, and 700 million by 2045. two-thirds of people with diabetes live in urban areas, and one in five people with diabetes is above 65 year. diabetic peripheral neuropathy is the most prevalent complication of diabetes mellitus. the prevalence of dpn ranges from 21.3 to 34.5% in type 2 dm (t2dm) and between seven to 34.2% in type 1 dm (t1dm). the high incidence and prevalence of falls among older people with type 2 diabetes mellitus were identified as poor diabetic control, diabetic peripheral neuropathy (dpn) and balance impairment. study performed by ahmed et al., reported that kinesio tape and resistive exercise improve the dorsiflexors and functional performance in diabetic polyneuropathy. a randomized controlled trial showed that wbv showed beneficial effects on pain, balance, and quality of life in patients with painful diabetic peripheral neuropathy. but till know no study reported us whole body vibration better than kineso or vice versa.

Eligibility criteria:
inclusion criteria: * patients type 2 diabetes with duration at least 10 years. * controlled blood glucose level examined via glycated hemoglobin exam (hba1cless than 9 and more than 6.5). * age of patient will range from 50 to 60 years. * patients had abnormal nerve conduction study. exclusion criteria: * patients having ulceration/infection of feet * medical/surgical conditions limiting functional mobility * non-ambulatory patients * who are not willing to participate? * subjects with type 1 diabetes mellitus. * subjects with gestational diabetes. * subjects who are seriously ill. * lower limb fracture or trauma * significant renal hepatic disorder
shorter radiation schedule for the treatment of prostate cancer

Conditions: Prostate Cancer

Summary: to improve the management of patients with early stage prostate cancer.

to compare the efficacy of a shorter radiation fractionation schedule to the prostate (5250 cgy/20 fractions over 28 days) with a conventional schedule (6600 cgy/33 fractions over 45 days) in men receiving radiotherapy for stage t1a moderately or poorly differentiated, or t1b, t1c, or t2 prostate cancer. the primary outcome is local control in the prostate and secondary outcomes include toxicity, disease free survival, survival, quality of life and economics.

Eligibility criteria:
inclusion criteria: * histologic diagnosis of adenocarcinoma of the prostate with no evidence of metastatic disease to the nodes, bone or lung * stage t1a moderately or poorly differentiated, t1b, t1c or t2 by the current uicc-tnm classification exclusion criteria: * psa \> 40 mcg/l * previous therapy for carcinoma of the prostate other than biopsy or turp, including patients previously on hormone therapy for treatment of their prostate cancer * prior or active malignancy other than non-melanoma skin cancer; or colon or thyroid cancer treated a minimum of five years prior to study entry and presumed cured * simulated volume exceeds 1000 cm3 * previous pelvic radiotherapy * inflammatory bowel disease * serious non-malignant disease which would preclude radiotherapy or surgical biopsy * geographic inaccessibility for follow-up * psychiatric or addictive disorder which would preclude obtaining informed consent or adherence to protocol * unable to commence radiation therapy within 26 weeks of the date of last prostatic biopsy * failure to give informed consent to participate in the study

Keywords: prostate cancer prostate specific antigen psa radiation fractionation
routine calcium for preventing hypocalcemia

Conditions: Thyroid Neoplasm

Summary: the present study investigated the effect of routine calcium and vitamin d supplementation and tried to find the predictors for postoperative hypocalcemia in patients with thyroid cancer.

the present study investigated the effect of routine calcium and vitamin d supplementation and tried to find the predictors for postoperative hypocalcemia in patients with thyroid cancer. demographic data, including age, sex, pathologic features, and postoperative laboratory test results were analyzed, as was the development of symptomatic hypocalcemia, defined as an ionized calcium concentration below 4.6 mg/dl (normal range, 4.6-5.4 mg/dl) associated with hypocalcemic symptoms. hypocalcemia was considered permanent in patients who required calcium supplementation for longer than 6 months after thyroidectomy. serum concentrations of pth and ionized calcium were measured 1 and 14 days postoperatively. patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium and 1,000 iu/day cholecalciferol for 2 weeks, beginning on the first postoperative day (pod) to the 14th pod, whereas patients in the control group received no supplementation. if symptomatic hypocalcemia developed, patients in both groups received 2.0 g of intravenous calcium, followed by oral supplementation with 3,000-4,000 mg/day elemental calcium and 1,000-2,000 iu/day cholecalciferol up to the 14th pod. if hypocalcemic symptoms were persistent or worsening 2 hours after calcium administration, patients were administered another intravenous calcium supplementation.

Eligibility criteria:
inclusion criteria: * patients with thyroid cancer * euthyroid state * underwent total thyroidectomy exclusion criteria: * previous history of neck surgery or irradiation * calcium supplement before enrollment * hyperthyroidism or hypothyroidism * pregnancy